Tech Company Inital Public Offerings
Black Diamond Therapeutics IPO
Headquartered in Cambridge, Black Diamond Therapeutics is now a public company.
Transaction Overview
Company Name
Announced On
1/29/2020
Transaction Type
IPO
Amount
$201,400,000
Proceeds Purpose
We intend to use the net proceeds of this offering to fund the Phase 1/2 development of BDTX-189, to identify a lead development candidate and conduct IND-enabling studies in our glioblastoma program and for continued development of our discovery programs and our MAP platform, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
139 Main St. 301
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Black Diamond Therapeutics (Nasdaq: BDTX): A Next-Wave Cancer Precision Medicine Company. Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Epstein
Chief Financial Officer
Thomas Leggett
Chief Operating Officer
Brent Hatzis-Schoch
Chief Scientific Officer
Christopher Roberts
Executive Vice President
Elizabeth Buck
Vice President
Tai-An Lin
Vice President
Matthew Lucas
Vice President
Nigel Waters
Vice President
Karsten Witt
Browse more venture capital transactions:
Prev: 1/28/2020: Teller venture capital transaction
Next: 1/29/2020: Terramera venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs